Entheon Biomedical Corp.: Entheon Biomedical Subsidiary, HaluGen Life Sciences, Announces Agreement with Psychedelics Today

Expanding brand awareness and access to HaluGen's Psychedelics Genetic Test Kit
Vancouver, British Columbia--(Newsfile Corp. - January 18, 2022) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE:

Related Keywords

United States ,Canada ,United Kingdom ,Bluesky ,Alberta ,Vancouver ,British Columbia ,British ,Canadian ,Timothy Ko ,Ryan Mccreanor ,Joseph Cullen ,Joe Moore ,Elizabeth Glassen ,Halugen Life Sciences Inc ,Halugen Life Sciences ,Bluesky Communications ,Entheon Biomedical Corp ,Psychedelic Education Center ,British Columbia Newsfile Corp ,European Union ,Canadian Securities Exchange ,Halugen Lobo Genetics Business Development ,Psychedelics Today ,Company Psychedelics Genetic Test Kit ,Psychedelics Genetic Test ,Psychedelics Genetic Test Kit ,Entheon Biomedical Chief Executive Officer ,Halugen Life ,Psychedelics Today Chief Executive Officer ,Lobo Genetics Business Development ,Entheon ,Iomedical ,Orp ,Ubsidiary ,Halugen ,Life ,Ciences ,Nnounces ,Agreement ,Psychedelics ,Oday ,